BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...